NATIONAL HARBOR, Md., Sept. 25, 2015 /PRNewswire-USNewswire/ -- This Sunday, September 27, six late breaking clinical trials will be discussed during the Heart Failure Society of America's 19th Annual Scientific Meeting. "Aquarpheresis Versus Diuretics and Hospitalization for Heart Failure Trial (AVOID-HF)" and "HeartMate 3 CE Mark Study", will both be presented for the first time anywhere as part of a session starting at 3:30 PM. AVOID HF will have simultaneous journal publication. Additionally, "Cupid 2: A Phase2b Trial Investigating the Efficacy and Safety of Intracoronary Administration of AAV/SERCA2a in Patients with Advanced Heart Failure" will be included in this session for the first ever presentation in the United States.
Three other late breaking trials will also be discussed, and the media is invited to attend. This session will be at the Gaylord National Harbor Convention Center, near Washington DC, in the Maryland B Ballroom. The Late Breaking Clinical Trial session is one of the most popular sessions of this scientific meeting, with an overall expected attendance of over 2000 physicians, research scientists, advanced practice nurses, and PharmDs.
In the United States, approximately 5.7 million patients aged ≥20 years have heart failure (HF), with 870,000 new cases diagnosed each year (data from 2005 to 2011). The American Heart Association estimates that the 2012 total cost for HF was $30.7 billion, of which 68% was due to direct medical costs. That cost is expected to increase to $70 billion by 2013.
The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. HFSA supports a multi-disciplinary clinical team approach for the preventions of and care for heart failure patients and is seeking to raise awareness about this devastating disease
SOURCE Heart Failure Society of America